论文部分内容阅读
AIM:To assess the peripheral T lymphocyte subsets in chronic hepatitis B virus(HBV) infection,and their dynamics in response to adefovir dipivoxil monotherapy.METHODS:Proportions and absolute counts of peripheral natural killer cells,B cells,CD8+,CD4+,CD8+ CD38+,CD8+CD28+ and CD4+CD28+ T cells were determined using three-color flow cytometry in chronic hepatitis B patients(n = 35),HBV carriers(n = 25) and healthy controls(n = 35).Adefovir dipivoxil was initiated in 17 chronic hepatitis B patients who were regularly followed for 72 wk,during which period the T cell subsets and serum viral load were measured at each follow-up point.RESULTS:The peripheral CD4+ T cell counts and CD8+ T cell counts decreased in chronic HBV infection.In chronic hepatitis B patients,proportions of CD8+CD38+ T cells were 62.0% ± 14.7%,much higher than those of HBV carriers and healthy con-trols.In the 13 hepatitis B patients who were treated and responded to adefovir dipivoxil,proportions of CD8+CD38+ T cells decreased from 53.9% ± 18.4% pre-therapy to 20.1% ± 11.3% by week 72(P < 0.001),concomitant with viral load decline(HBV DNA fell from 7.31 to 3 log copies/mL).CD8+ T cell counts also underwent an average increase of 218 cells/μL by the end of 72-wk treatment.In those who failed the therapy,the CD8+CD38+ T cell population had more fluctuations.CONCLUSION:CD8+ T cells abnormally activated in chronic HBV infection can be partially reversed by antiviral therapy.HBV-associated immune activation may be a crucial part of the pathogenesis and a promising target of treatment.
AIM: To assess the peripheral T lymphocyte subsets in chronic hepatitis B virus (HBV) infection, and their dynamics in response to adefovir dipivoxil monotherapy. METHODS: Proportions and absolute counts of peripheral natural killer cells, B cells, CD8 +, CD4 +, CD8 + CD38 + , CD8 + CD28 + and CD4 + CD28 + T cells were determined using three-color flow cytometry in chronic hepatitis B patients (n = 35), HBV carriers 17 chronic hepatitis B patients who were regularly followed for 72 wk, during which period the T cell subsets and serum viral load were measured at each follow-up point .RESULTS: The peripheral CD4 + T cell counts and CD8 + T cell counts decreased in chronic HBV proportions of CD8 + CD38 + T cells were 62.0% ± 14.7%, much higher than those of HBV carriers and healthy con- trols. In the 13 hepatitis B patients who were treated and responded to adefovir dipivoxil, proportions of CD8 + CD38 + T cells decreased from 53.9% ± 18.4% pre-therapy to 20.1% ± 11.3% by week 72 (P <0.001), concomitant with viral load decline (HBV DNA fell from 7.31 to 3 log copies / mL) an average increase of 218 cells / μL by the end of 72-wk treatment.In those who failed the therapy, the CD8 + CD38 + T cell population had more fluctuations.CONCLUSION: CD8 + T cells abnormally activated in chronic HBV infection can be reversed by antiviral therapy. HBV-associated immune activation may be a part part of the pathogenesis and a promising target of treatment.